Schellenberg Wittmer advises Bioventure on Series B Financing Round of the Swiss Aphaia Companies
Schellenberg Wittmer has advised Bioventure Club Deal Nine & Co KG on a Series B Financing Round of the Swiss Aphaia Companies, which are clinical stage pharma companies that have developed proprietary treatment methods targeting obesity and associated metabolic diseases.
The corporate/m&a team consisted of partner Oliver Triebold (pictured), Elia Claude Schunck (associate), Laura Roth (trainee lawyer) and also included partner Michael Nordin and senior associate Roland Wild (both tax).
